治疗提醒应用对成年人Beta-thalassemia重大治疗坚持的影响:一个随机临床试验
Fatemeh Mehrabadi1,2, Mahdieh Arian2,3, Zahra Badiee4
1Department of Intensive Care Nursing, School of Nursing and Midwifery, Mashhad University of Medical Sciences, Mashhad, Iran.
Iranian journal of medical sciences
|September 22, 2025
概括
一个治疗提醒应用程序显著改善了成人β-thalassemia主要患者的治疗坚持. 这种数字工具增强了药物管理和患者参与度,解决了慢性疾病护理的关键挑战.
科学领域:
- 血液学 血液学 血液学
- 医疗信息学 医疗信息学
- 临床药房 临床药房
背景情况:
- 治疗不坚持是管理β-thalassemia major (BTM) 的一个重大挑战.
- 有效的疾病管理策略对于改善BTM患者的治疗结果至关重要.
- 这项研究解决了对创新解决方案的需求,以提高BTM患者的治疗坚持.
研究的目的:
- 评估治疗提醒应用对成年BTM患者治疗坚持的影响.
- 评估数字卫生干预措施在改善药物服药的有效性.
- 探索技术在支持慢性疾病管理中的作用.
主要方法:
- 一项随机临床试验与76名成年BTM患者进行.
- 参与者被分配到使用ThalaMe应用程序的干预组或接受标准护理8周的对照组.
- 使用莫里斯基药物坚持度表 (MMAS-8) 和慢性疾病治疗坚持问卷 (CDTAQ) 测量了药物坚持度.
主要成果:
- 使用ThalaMe应用程序的干预组与对照组相比,显示出明显更好的坚持结果 (P<0.001).
- 在ThalaMe应用程序组实现显著更高的CDTAQ得分,表明改善了治疗坚持 (P<0.001).
- 干预前的基线坚持得分 (MMAS-8和CDTAQ) 在干预前的组之间没有显著差异.
结论:
- 治疗提醒应用程序显著提高了BTM患者的药物坚持和治疗管理.
- 数字干预还通过综合咨询改善了患者和家庭的参与.
- 该ThalaMe应用程序代表了一个有前途的工具,以改善在慢性疾病如BTM的坚持.
相关概念视频
Drug Therapy
245
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
245
Therapeutic Drug Monitoring: Affecting Factors
202
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
202
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Blinding
3.8K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.8K
Clinical Trials
10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.2K
Therapeutic Drug Monitoring: Overview and Classification
312
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
312


